SCHEMBL4569893

SCHEMBL4569893

CC(=O)c1sccc1NS(=O)(=O)c1ccccc1-c1ccncc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC10A6 Q3KNW5 1/20 0.46
EDNRA P25101 7/20 0.42
EDNRB P24530 3/20 0.42
NPSR1 Q6W5P4 2/20 0.40
MAPK8 P45983 2/20 0.40
MAPK10 P53779 2/20 0.40
KCNH2 Q12809 1/20 0.40
PRNP P04156 1/20 0.40
PPARG P37231 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
NCOR2 Q9Y618 1/20 0.40
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
POLB P06746 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
IMPDH2 P12268 1/20 0.38
NAMPT P43490 1/20 0.38
CKS1B P61024 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4569888 0.87 SLC10A6 (0.45) SLC10A6EDNRAEDNRBNPSR1MAPK8
SCHEMBL4569892 0.84 SLC10A6 (0.44) SLC10A6EDNRAEDNRBNPSR1MAPK8
SCHEMBL13552623 0.83 SLC10A6 (0.42) SLC10A6EDNRAEDNRBNPSR1MAPK8
SCHEMBL4569889 0.81 BRD4 (0.48) SLC10A6NPSR1MAPK8MAPK10KCNH2
SCHEMBL4569883 0.78 NPSR1 (0.50) NPSR1RXFP1LMNAHPGDTSHR
SCHEMBL4569890 0.77 EDNRA (0.45) SLC10A6EDNRAEDNRB
SCHEMBL10068134 0.76 NRP1 (0.37) SLC10A6EDNRAEDNRBNAMPTBCL2
SCHEMBL4569891 0.75 PTGES2 (0.47) SLC10A6
SCHEMBL8222246 0.74 NRP1 (0.56)
SCHEMBL13552673 0.73 SLC10A6 (0.42) SLC10A6EDNRAEDNRBNPSR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8227606-B2 Arginine derivatives with NP-1 antagonistic activity ARK THERAPEUTICS, LTD. (GB) 2012-07-24 US disclosed
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY GB06/019611.7 THERAPIES LIMITED (GB) 2012-05-17 US disclosed
US-8158789-B2 Arginine derivatives with NP-I antagonistic activity Ark Therapeutics Group Ltd. (GB) 2012-04-17 US disclosed
US-20100022525-A1 Arginine Derivatives with NP-I Antagonistic Activity GB06/019611.7 THERAPIES LIMITED (GB) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122862-A1 ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY NPFFR1, NPR1, ARG1 SLC10A6 1440/4885EDNRA 18/4885EDNRB 28/4885
US-20100022525-A1 Arginine Derivatives with NP-I Antagonistic Activity NPFFR1, NPR1, ARG1 SLC10A6 1440/4885EDNRA 18/4885EDNRB 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.